Recognizing the sight of blood in urine, the most common first sign of bladder cancer, is often the impetus that leads people ...

A large U.S. health records study suggests that difficulty seeing blood in urine may put color-blind patients at higher risk.

Out of sight, out of mind. A new study suggests a common eye condition could be quietly masking one of the only early warning ...

People with color blindness may be less able to spot an early sign of bladder cancer, making them likelier to be diagnosed ...

No significant difference seen between patients with colorectal cancer and color vision deficiency versus those without color vision deficiency.

"With its potential for screening, recurrence monitoring, treatment guidance, and prognosis prediction, utDNA is poised to transform bladder cancer management and personalize patient care." — Liang ...

Although bladder cancer ranks as the sixth most common cancer in the United States, with approximately 85,000 new cases diagnosed each year, it continues to receive limited awareness, advocacy, and ...

Signatera detects molecular residual disease in bladder cancer by identifying tumor DNA fragments in the bloodstream, even when not visible on scans. The IMvigor010 trial showed that Signatera-guided ...

Inlexzo is a new treatment for a type of bladder cancer in adults that hasn’t spread to the muscles and doesn’t respond to Bacillus Calmette-Guérin (BCG) therapy. It’s approved for treating non-muscle ...